Nanoemulsion Adjuvant
Nanoemulsion Adjuvant - Related Videos
01:50
Preparation of a Nanoemulsion Adjuvant Vaccine
0 Views •
2025
This video demonstrates the production of nanoemulsion tumor vaccines. The stable oil reservoir depots carrying synthetic peptides and adjuvants are produced by low-energy nanoemulsion, offering significant promise for tumor immunotherapy.
08:15
In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
0 Views •
Cited by 2 •
2022
The protocol presents detailed methods for evaluating whether the nanoemulsion ophiopogonin D adjuvant promotes effective cellular immune responses.
07:32
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
0 Views •
Cited by 1 •
2023
The present protocol prepares and evaluates the physical properties, immune response, and in vivo protective effect of a novel nanoemulsion adjuvant vaccine.
06:02
Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
0 Views •
Cited by 2 •
2024
In this protocol, we developed a cationic nanoemulsion-encapsulated retinoic acid (RA) to be used as an adjuvant to promote antigen-specific systemic and mucosal responses. By adding the FDA-approved RA to the nanoemulsion, antigen-specific sIgA was promoted in the vagina and small intestine after intramuscular injection of the nanoemulsion.
03:29
A Technique to Generate an Adjuvant-Induced Arthritis Mouse Model
0 Views •
2025
This video demonstrates a method to generate adjuvant-induced arthritis in a murine model. Complete Freund's adjuvant (CFA) is injected in the mouse ankle joint and periarticular areas. CFA activates the immune system, leading to neutrophil infiltration and exaggerated inflammation.
FAQs
The finely dispersed droplets increase contact between the vaccine formulation and immune cells, which can promote antigen uptake by antigen-presenting cells. Once these cells acquire antigen, they can support antigen presentation, a process that helps direct subsequent lymphocyte activation. This mechanism connects the formulation’s physical structure with the development of an adaptive immune response.
The emulsion’s physicochemical properties can stimulate local innate immune signals near the vaccination site. These signals help create conditions that support antigen presentation and lymphocyte activation rather than relying only on the antigen itself. Consequently, formulation properties become important variables when researchers investigate how to strengthen or shape vaccine-induced immunity.
Its composition can be adjusted as part of investigating vaccine delivery systems with different immune effects. This tunability allows researchers to study how formulation characteristics relate to response magnitude, durability, or breadth. Such comparisons are relevant when seeking safer and more effective approaches for presenting antigens and supporting immune activation.
Evaluation can focus on whether the formulation improves the magnitude, durability, or breadth of the response to an antigen. Magnitude concerns response strength, durability concerns how long the response is maintained, and breadth concerns the range of immune recognition. Considering all three helps distinguish a stronger response from a more persistent or broadly useful one.
Researchers can evaluate these formulations in vaccines directed against viral, bacterial, and other pathogens. The relevant question is whether the adjuvanted formulation can improve the immune response generated against the selected pathogen’s antigen. This makes the approach applicable across multiple infection research areas rather than restricting it to a single pathogen class.
In immunology and infection research, these formulations provide a way to investigate how delivery characteristics and local innate signals influence antigen presentation and lymphocyte activation. Studies can therefore connect formulation design with vaccine performance against infectious targets. The broader goal is to develop delivery systems that support safer, more effective, and appropriately shaped immune responses.